This company listing is no longer active
LexaGene Holdings Management
Management criteria checks 2/4
Key information
Jack Regan
Chief executive officer
US$482.4k
Total compensation
| CEO salary percentage | 70.2% |
| CEO tenure | 6.6yrs |
| CEO ownership | 4.3% |
| Management average tenure | 5.8yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
It's Unlikely That LexaGene Holdings Inc.'s (CVE:LXG) CEO Will See A Huge Pay Rise This Year
Feb 02
We're A Little Worried About LexaGene Holdings' (CVE:LXG) Cash Burn Rate
Oct 07Here's Why We're Not Too Worried About LexaGene Holdings' (CVE:LXG) Cash Burn Situation
May 17We Think LexaGene Holdings (CVE:LXG) Can Afford To Drive Business Growth
Feb 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Nov 30 2022 | n/a | n/a | -US$9m |
| Aug 31 2022 | n/a | n/a | -US$10m |
| May 31 2022 | n/a | n/a | -US$10m |
| Feb 28 2022 | US$482k | US$338k | -US$11m |
| Nov 30 2021 | n/a | n/a | -US$11m |
| Aug 31 2021 | n/a | n/a | -US$11m |
| May 31 2021 | n/a | n/a | -US$11m |
| Feb 28 2021 | US$466k | US$250k | -US$10m |
| Nov 30 2020 | n/a | n/a | -US$9m |
| Aug 31 2020 | n/a | n/a | -US$9m |
| May 31 2020 | n/a | n/a | -US$8m |
| Feb 29 2020 | US$375k | US$250k | -US$7m |
| Nov 30 2019 | n/a | n/a | -US$8m |
| Aug 31 2019 | n/a | n/a | -US$8m |
| May 31 2019 | n/a | n/a | -US$8m |
| Feb 28 2019 | US$300k | US$240k | -US$8m |
| Nov 30 2018 | n/a | n/a | -US$7m |
| Aug 31 2018 | n/a | n/a | -US$7m |
| May 31 2018 | n/a | n/a | -US$5m |
| Feb 28 2018 | US$200k | US$200k | -US$4m |
| Nov 30 2017 | n/a | n/a | -US$3m |
| Aug 31 2017 | n/a | n/a | -US$6m |
| May 31 2017 | n/a | n/a | -US$5m |
| Feb 28 2017 | US$180k | US$180k | -US$4m |
Compensation vs Market: Jack's total compensation ($USD482.44K) is above average for companies of similar size in the Canadian market ($USD177.69K).
Compensation vs Earnings: Jack's compensation has increased whilst the company is unprofitable.
CEO
Jack Regan (49 yo)
6.6yrs
Tenure
US$482,437
Compensation
Dr. John F. Regan, also known as Jack, is the Founder of LexaGene Holdings Inc. since 2016 and has been its Chairman of the Board since September 12, 2017 and its Chief Executive Officer and Director since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.6yrs | US$482.44k | 4.3% CA$ 636.1k | |
| CFO, Treasurer & Corporate Secretary | 5.2yrs | US$344.52k | 0.11% CA$ 16.0k | |
| Chief Operating Officer | 2.8yrs | US$268.40k | 0.28% CA$ 41.8k | |
| Vice President of Corporate Development | 6.5yrs | no data | no data | |
| Director of Corporate Marketing | no data | no data | no data | |
| Vice President of Capital Markets | no data | no data | no data |
5.8yrs
Average Tenure
54yo
Average Age
Experienced Management: LXG.H's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.6yrs | US$482.44k | 4.3% CA$ 636.1k | |
| Independent Director | 4.9yrs | US$98.81k | 0.0073% CA$ 1.1k | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Independent Director | 6.6yrs | US$137.68k | 0% CA$ 0 | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Independent Director | 2.3yrs | US$164.83k | 0% CA$ 0 | |
| Independent Director | 1.5yrs | US$92.35k | 0% CA$ 0 |
4.3yrs
Average Tenure
62yo
Average Age
Experienced Board: LXG.H's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/21 18:42 |
| End of Day Share Price | 2023/02/21 00:00 |
| Earnings | 2022/11/30 |
| Annual Earnings | 2022/02/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LexaGene Holdings Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sally Yanchus | Brookline Capital Markets |
| Neil Linsdell | iA Capital Markets |
| Chelsea Stellick | iA Capital Markets |